Saphnelo, the first drug of its kind to treat systemic lupus erythematosus, has landed in the Greater Bay Area
我放心你带套猛
发表于 昨天 16:44
121
0
0
Thanks to the "Hong Kong Macau Medical Device Connect" policy in the Greater Bay Area, the first batch of Afulimumab has recently landed at the University of Hong Kong Shenzhen Hospital. AstraZeneca announced today that Saphnelo (Anifrolumab/Afulimumab) has been approved by the Guangdong Provincial Drug Administration and officially introduced into designated medical institutions in the Guangdong Hong Kong Macao Greater Bay Area for use as an additional therapy for adult patients with moderate to severe active systemic lupus erythematosus who still have positive autoantibodies and receive standard treatment.
Professor Zeng Xiaofeng, the lead PI of AZALEA Phase III clinical study in Asia and a professor at Peking Union Medical College Hospital, stated that systemic lupus erythematosus is a common autoimmune rheumatic disease, but currently there is a severe lack of drugs that can balance efficacy and safety in clinical practice. Afulimumab is a monoclonal antibody that targets type I interferon receptors and is also a novel targeted drug. The approval of early use of afliumab in the Greater Bay Area through the 'Hong Kong Macau Medical Device Connect' policy is good news for SLE patients and clinical doctors. In addition, the AZALEA phase III clinical study of afliumab in Asia is also underway in China, and we hope that the drug can be fully approved as soon as possible
The side effects caused by long-term use of hormones are an unavoidable issue in the clinical treatment of SLE. We are pleased that we have been able to introduce the breakthrough innovative therapy of afliumab through the 'Hong Kong Macau Medical Device Connect'. We hope that with the help of this drug, patients can better control disease activity, improve prognosis, and enhance their quality of life, "said Professor Zhang Lijun, Director of the Rheumatology and Immunology Department at the University of Hong Kong Shenzhen Hospital.
Chen Xi, Vice President of AstraZeneca China and Head of the Respiratory and Autoimmune Biopharmaceuticals, Vaccines, and Immunotherapy Business Unit, stated that Afulimumab is AstraZeneca's first innovative product in the field of autoimmunity in China, and they are pleased to be able to land in the Greater Bay Area through the "Hong Kong Macau Medical Device Connect" fast track. Wu Shan, General Manager of AstraZeneca in Hong Kong and Macau, stated that the Greater Bay Area has a solid foundation and broad prospects for the development of the biopharmaceutical and health industries. Thanks to the "Hong Kong Macau Medical Device Connect" policy, the pharmaceutical resources of Guangdong, Hong Kong, and Macau are rapidly benefiting residents in the Greater Bay Area.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
-
英偉達氏はインドと人工知能チップの共同開発について初歩的な交渉を行っているという。
- 宁郎
- 13 分钟前
- 支持
- 反对
- 回复
- 收藏
-
2024年のダブル11電子商取引フェスティバルで、アップルが発表してからわずか1カ月のiPhone 16シリーズ全シリーズが値下げを迎えたことが21日、明らかになった。これは新機が発表されて以来、公式チャンネルでの値 ...
- 愿为素心人
- 昨天 21:36
- 支持
- 反对
- 回复
- 收藏
-
【NVIDIA GPUレンタル価格が腰砕け!H 100とRTX 4090は共に50%急落】メディアの報道によると、最近、NVIDIA GPUレンタル市場は激しい価格変動を経験した。特にH 100とコンシューマークラスのグラフィックスカードRT ...
- 什么大师特
- 昨天 19:42
- 支持
- 反对
- 回复
- 收藏
-
天風国際証券アナリストの郭明錤氏が最近発表した英偉達Blackwell GB 200チップの産業チェーン受注情報によると、現在マイクロソフトは世界最大のGB 200顧客で、今年第4四半期の受注量は3-4倍に急増し、受注量は他 ...
- 123458104
- 前天 10:03
- 支持
- 反对
- 回复
- 收藏